Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer
Over the past 5 years, checkpoint inhibitors including anti-CTLA-4 and anti-PD-1/PD-L1 blockers have changed approaches to therapy of metastatic renal cell cancer. However, more than 55 % of patients with advanced kidney cancer remain resistant to immunotherapy. This paper refects the causes that le...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2023-09-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/2686 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699941642928128 |
|---|---|
| author | A. A. Izmailov R. R. Rakhimov A. V. Sultanbayev K. V. Menshikov I. R. Gilyazova V. M. Zabelin A. A. Izmailov |
| author_facet | A. A. Izmailov R. R. Rakhimov A. V. Sultanbayev K. V. Menshikov I. R. Gilyazova V. M. Zabelin A. A. Izmailov |
| author_sort | A. A. Izmailov |
| collection | DOAJ |
| description | Over the past 5 years, checkpoint inhibitors including anti-CTLA-4 and anti-PD-1/PD-L1 blockers have changed approaches to therapy of metastatic renal cell cancer. However, more than 55 % of patients with advanced kidney cancer remain resistant to immunotherapy. This paper refects the causes that lead to primary and acquired resistance to immune checkpoint inhibitors during the treatment of metastatic renal cell cancer. The purpose of the study was to elucidate the mechanisms underlying resistance to checkpoint inhibitors during the treatment of metastatic kidney cancer. Material and Methods. A literature search was conducted using Pubmed database in the time interval between 2010 and 2023. We identifed 286 publications of which 59 were relevant for our review. Results. There are many factors that contribute to primary or acquired resistance to immunotherapy, including factors associated with the tumor cell as well as tumor microenvironment factors. Conclusion. Many innovative approaches to overcoming resistance to monoclonal antibodies are being investigated in clinical trials. In connection with the advent of new methods, the cellular composition of the tumor microenvironment and its role in the emergence of tumor resistance to immunotherapy are becoming increasingly clear. New biomarkers are emerging to help identify the best candidates for immunotherapy in metastatic kidney cancer. However, they require further study. |
| format | Article |
| id | doaj-art-c09d80d42bcb44f89c9ea3942409b438 |
| institution | DOAJ |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2023-09-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-c09d80d42bcb44f89c9ea3942409b4382025-08-20T03:18:26ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682023-09-0122410911710.21294/1814-4861-2023-22-4-109-1171148Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancerA. A. Izmailov0R. R. Rakhimov1A. V. Sultanbayev2K. V. Menshikov3I. R. Gilyazova4V. M. Zabelin5A. A. Izmailov6Republican Clinical Oncology Center of the Ministry of Health of the Republic of BashkortostanRepublican Clinical Oncology Center of the Ministry of Health of the Republic of BashkortostanRepublican Clinical Oncology Center of the Ministry of Health of the Republic of BashkortostanRepublican Clinical Oncology Center of the Ministry of Health of the Republic of Bashkortostan; Bashkir State Medical University of the Ministry of Health of the RussiaBashkir State Medical University of the Ministry of Health of the Russia; Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of SciencesN.I. Pirogov Russian National Research Medical University of the Ministry of Health of RussiaP.A. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre of the Ministry of Health of the RussiaOver the past 5 years, checkpoint inhibitors including anti-CTLA-4 and anti-PD-1/PD-L1 blockers have changed approaches to therapy of metastatic renal cell cancer. However, more than 55 % of patients with advanced kidney cancer remain resistant to immunotherapy. This paper refects the causes that lead to primary and acquired resistance to immune checkpoint inhibitors during the treatment of metastatic renal cell cancer. The purpose of the study was to elucidate the mechanisms underlying resistance to checkpoint inhibitors during the treatment of metastatic kidney cancer. Material and Methods. A literature search was conducted using Pubmed database in the time interval between 2010 and 2023. We identifed 286 publications of which 59 were relevant for our review. Results. There are many factors that contribute to primary or acquired resistance to immunotherapy, including factors associated with the tumor cell as well as tumor microenvironment factors. Conclusion. Many innovative approaches to overcoming resistance to monoclonal antibodies are being investigated in clinical trials. In connection with the advent of new methods, the cellular composition of the tumor microenvironment and its role in the emergence of tumor resistance to immunotherapy are becoming increasingly clear. New biomarkers are emerging to help identify the best candidates for immunotherapy in metastatic kidney cancer. However, they require further study.https://www.siboncoj.ru/jour/article/view/2686kidney cancerresistancecheckpoint inhibitors |
| spellingShingle | A. A. Izmailov R. R. Rakhimov A. V. Sultanbayev K. V. Menshikov I. R. Gilyazova V. M. Zabelin A. A. Izmailov Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer Сибирский онкологический журнал kidney cancer resistance checkpoint inhibitors |
| title | Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer |
| title_full | Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer |
| title_fullStr | Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer |
| title_full_unstemmed | Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer |
| title_short | Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer |
| title_sort | resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer |
| topic | kidney cancer resistance checkpoint inhibitors |
| url | https://www.siboncoj.ru/jour/article/view/2686 |
| work_keys_str_mv | AT aaizmailov resistancetoimmunecheckpointinhibitorsinthetreatmentofmetastaticrenalcancer AT rrrakhimov resistancetoimmunecheckpointinhibitorsinthetreatmentofmetastaticrenalcancer AT avsultanbayev resistancetoimmunecheckpointinhibitorsinthetreatmentofmetastaticrenalcancer AT kvmenshikov resistancetoimmunecheckpointinhibitorsinthetreatmentofmetastaticrenalcancer AT irgilyazova resistancetoimmunecheckpointinhibitorsinthetreatmentofmetastaticrenalcancer AT vmzabelin resistancetoimmunecheckpointinhibitorsinthetreatmentofmetastaticrenalcancer AT aaizmailov resistancetoimmunecheckpointinhibitorsinthetreatmentofmetastaticrenalcancer |